Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company with a focus on the development of pioneering cell and exosome-based therapeutics, has welcomed Philip J. Gotwals, Ph.D. to its Board of Directors.
Joining from Novartis Institutes for Biomedical Research, where he served as Global Head, Vice President of Business Development and Licensing, Dr. Gotwals brings his considerable experience and industry insights to the company, offering strategic insight into research, innovation and drug development.
We are thrilled to welcome Philip to our Board of Directors! His extensive experience in drug discovery and commercialization, along with his scientific expertise and strategic business development capabilities, make him a substantial asset to our team as we continue to develop and progress our cell and exosome technologies. We are excited to have Philip on board and look forward to the impact of his contributions.
Dr. Gotwals is ecstatic to become a part of Capricor’s board of directors. The encouraging results obtained thus far suggest that CAP-1002 has a promising future and could become a dependable treatment for Duchenne muscular dystrophy if approved by regulatory authorities.
Moreover, the StealthX™ exosome platform has made remarkable commendable strides and is projected to revolutionize the world of vaccinology and become the go-to for targeted oligonucleotide, protein, and small molecule therapeutics. Dr. Gotwals is looking forward to working with the Capricor team to further their mission in any way possible.
Dr. Gotwals has a long and illustrious career in the biotechnology industry, spanning almost 30 years of expertise in drug development, research, and corporate and business strategy. Most recently, he served as the Global Head and Vice President of Business Development and Licensing at Novartis Institutes for Biomedical Research (NIBR), where he entered into over 50 strategic transactions aimed at driving corporate evolution and growth.
Prior to NIBR, he held positions of Vice President of Program Management at Altus Pharmaceuticals and Senior Director of Program and Alliance management at Biogen. His background academically consists of a B.A. in Biology from Amherst College, and a Ph.D. in Genetics from the University of California at Berkeley, plus postdoctoral research at MIT. Dr. Gotwals has published extensively in the area of integrin biology, to serve as a stalwart authority in the field.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a pioneer in the exciting field of biotechnology, pushing the boundaries to develop revolutionary therapeutics from cellular and exosomal sources. Their lead candidate, CAP-1002, is an advanced allogeneic cardiac-derived cell therapy, currently in its late stages of clinical development for treating Duchenne muscular dystrophy.
On top of this, Capricor has teamed up with NS Pharma, Inc. for the commercialization and distribution of CAP-1002 for the American and Japanese markets, pending regulatory approval. Additionally, Capricor is exploring further possibilities with its exosome technology; a next-generation therapeutic platform capable of delivering nucleic acids and proteins to treat and prevent a wide range of diseases.